Thyroid disorders affect bone far more than most people realize. Both an overactive thyroid (hyperthyroidism) and, in different ways, an underactive thyroid (hypothyroidism) can change how quickly your skeleton builds and breaks down bone tissue. The bone symptoms range from subtle decreases in bone density that show up only on a scan to full-blown osteoporosis with fractures, and in children, stunted growth and delayed skeletal development. What makes this tricky is that the bone-related effects often develop silently, sometimes even when thyroid blood tests look only mildly abnormal.
How Thyroid Hormones Influence Your Skeleton
Your bones are not static structures. They are constantly being remodeled: specialized cells called osteoclasts break down old bone, and osteoblasts lay down new bone in its place. Thyroid hormones have a direct hand in controlling both sides of this cycle. The active thyroid hormone T3 drives bone-building during childhood and adolescence but shifts toward accelerating bone breakdown in adults.1PubMed. Mechanisms of action of thyroid hormones in the skeleton That same hormone, when present in excess, ramps up osteoclast activity and even increases bone cells’ sensitivity to inflammatory signals that promote further resorption.2PubMed Central. Hyperthyroidism-associated hypercalcemic crisis: A case report and review of the literature
There is also a separate layer of regulation that often gets overlooked: TSH itself, the pituitary hormone that tells your thyroid to make more hormone, has its own direct effect on bone. TSH receptors sit on the surfaces of both osteoblast and osteoclast precursors. TSH acts as a brake on bone resorption, meaning it helps preserve bone mass independently of thyroid hormone levels.3PubMed. TSH is a negative regulator of skeletal remodeling Animal studies confirm this: mice lacking TSH receptors had lower bone strength, reduced trabecular bone volume, and increased osteoclast surfaces even when thyroid hormone levels were corrected.4PubMed. Thyroid-stimulating hormone maintains bone mass and strength by suppressing osteoclast differentiation This dual effect matters clinically because some treatments suppress TSH on purpose, which can remove that protective brake even when thyroid hormone levels appear well controlled.
Hyperthyroidism and Bone Loss
If your thyroid is overactive, your bones pay a price. Thyrotoxicosis is a recognized cause of secondary osteoporosis, meaning osteoporosis triggered by another medical condition rather than by aging alone.5PubMed Central. Role of Thyroid Hormones in Skeletal Development and Bone Maintenance The excess thyroid hormone speeds up the entire bone remodeling cycle, but breakdown outpaces rebuilding. The result is a net loss of bone mineral density (BMD).6PubMed Central. IMPACT OF GRAVES’ DISEASE AND ANTITHYROID DRUG THERAPY ON BONE MINERAL DENSITY – PATHOPHYSIOLOGICAL MECHANISMS AND CLINICAL RELEVANCE
People with uncontrolled hyperthyroidism may not notice bone symptoms at first. The classic complaints of weight loss, rapid heartbeat, anxiety, and heat intolerance tend to dominate. But bone density can decline quietly in the background. In severe or prolonged cases, fractures become a real concern. Postmenopausal women with overt hyperthyroidism face roughly three to four times the fracture risk compared to women with normal thyroid function.7Endocrinology and Metabolism. Evaluation and Management of Bone Health in Patients with Thyroid Diseases: A Position Statement of the Korean Thyroid Association In peri- and postmenopausal women, the risk of vertebral fractures with hyperthyroidism is particularly stark.8PubMed Central. Thyroid Dysfunction in Peri- and Postmenopausal Women-Cumulative Risks
There is an additional wrinkle for people with Graves’ disease specifically. Graves’ disease produces thyroid-stimulating antibodies (TSAb) that mimic TSH but do not have the same bone-protective effect. Recent research found that TSAb actually inhibits osteoblast differentiation, the process by which new bone-forming cells mature, and worsened bone loss in animal models of Graves’ disease.9PubMed. TSAb inhibits osteogenic differentiation of MC3T3-E1 cells and exacerbates bone loss in Graves’ disease mice So in Graves’ disease, bone loss is driven by both excess thyroid hormone and these antibodies working against bone formation from a separate angle.
How Hypothyroidism Affects Bone
An underactive thyroid changes bone metabolism in a different direction. Overt hypothyroidism slows down both bone resorption and bone formation, essentially putting the whole remodeling process on pause. Interestingly, this slowdown can actually increase bone mineralization, because existing bone has more time to accumulate minerals before being broken down.10PubMed Central. Thyroid Hormone Diseases and Osteoporosis On the surface, that sounds protective. And in some populations, it appears to be: one study of over 4,700 postmenopausal women found that subclinical hypothyroidism was actually associated with a lower risk of osteoporosis compared to normal thyroid function.11PubMed. Subclinical thyroid dysfunction, bone mineral density, and osteoporosis in a middle-aged Korean population
But “more mineralized” does not always mean “stronger.” Bone needs a balance between mineral content and flexibility. If it becomes too heavily mineralized without adequate turnover, it can become brittle. Research on mice lacking the enzyme that converts thyroid hormone locally in bone cells (the type 2 deiodinase, or D2) showed bones that were more mineralized but also 50% less able to form new bone, making them more susceptible to fracture.12PubMed Central. Optimal bone strength and mineralization requires the type 2 iodothyronine deiodinase in osteoblasts So even though hypothyroidism does not typically cause osteoporosis the way hyperthyroidism does, it can compromise bone quality in subtler ways that do not always show up on a standard bone density scan.
When Thyroid Tests Look Only Mildly Abnormal
A lot of people have thyroid levels that are slightly off without full-blown thyroid disease. This is called subclinical thyroid dysfunction. For bone health, the two forms are not created equal.
Subclinical hyperthyroidism, where TSH is low but thyroid hormone levels are still in the normal range, carries real bone risk. A large analysis pooling data from multiple studies found a roughly 17% increase in the risk of any fracture and nearly double the risk of spine fracture in people with subclinical hyperthyroidism.13PubMed. Association of subclinical thyroid dysfunction with bone mineral density and fracture: a meta-analysis of prospective cohort studies A separate study confirmed the association, finding about a 34% increase in fracture risk that held up even after accounting for other risk factors like age, sex, and lifestyle habits.14JAMA Network Open. Association Between Subclinical Thyroid Dysfunction and Fracture Risk Subclinical hypothyroidism, on the other hand, showed no increased fracture risk in that same analysis.
This distinction matters because subclinical hyperthyroidism is often asymptomatic. You might feel perfectly fine while your bones are slowly losing density. It is frequently discovered only incidentally during routine blood work. But the evidence increasingly suggests that even this mild hormonal shift is enough to affect bone, particularly in postmenopausal women and older adults.
TSH Suppression Therapy and Bone
People treated for differentiated thyroid cancer often take higher-than-usual doses of thyroid hormone after surgery, deliberately pushing their TSH levels very low to reduce the chance of cancer recurrence. This TSH suppression therapy creates a form of subclinical (or sometimes overt) hyperthyroidism by design. The bone consequences depend heavily on how long suppression lasts and who the patient is.
Research using PET/CT imaging found that long-lasting TSH suppression caused a significant decrease in bone density and a higher likelihood of osteoporosis, while short-term suppression did not produce significant bone loss.15Scientific Reports. Effects of short- and long-term TSH suppression on lumbar bone mineral density in both genders using PET/CT Among women specifically, a study looking at long-term suppression therapy (averaging over seven years) found that premenopausal women showed no meaningful decline in bone density, but postmenopausal women with full TSH suppression trended toward lower BMD at the spine and hip.16PubMed Central. Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma The take-home: if you are postmenopausal and on long-term TSH suppression, bone density monitoring is especially important.
There is also emerging evidence that TSH suppression can blunt the effectiveness of osteoporosis drugs. A recent study found that patients on TSH suppression therapy who also had osteoporosis showed significantly less bone density improvement from zoledronic acid (a common osteoporosis medication) compared to osteoporosis patients with normal TSH levels. Bone turnover markers also stayed elevated in the suppressed group, suggesting the treatment was working against a current of ongoing excess resorption.17PubMed Central. TSH suppression attenuates the early efficacy of zoledronic acid in osteoporosis This is a practical concern for cancer survivors managing both recurrence risk and bone health simultaneously.
Children and Skeletal Development
In children, the stakes are different because the skeleton is still growing. Thyroid hormones are essential for normal bone maturation, growth plate function, and overall height attainment. When a child has prolonged hypothyroidism, the hallmark skeletal findings are delayed bone age (bones that look younger than the child’s actual age on X-ray), short stature, and thickened bands at the ends of long bones.18PubMed Central. Skeletal manifestations of juvenile hypothyroidism and the impact of treatment on skeletal system Linear bone growth slows, and epiphyseal mineralization largely stops.19IntechOpen. Growth in Children with Thyroid Dysfunction
Children with prolonged acquired hypothyroidism, such as from Hashimoto’s thyroiditis, can develop decreased linear growth and delayed bone age that may be severe enough to resemble rickets in some cases.20Endocrinology, Diabetes and Metabolism Case Reports. Rickets in a child with prolonged acquired hypothyroidism secondary to Hashimoto’s thyroiditis The other side of the coin also exists: neonatal hyperthyroidism can cause accelerated skeletal maturation, premature fusion of skull bones, and shortened fingers.21PubMed. Neonatal hyperthyroidism with accelerated skeletal maturation, craniosynostosis, and brachydactyly
During very early fetal development, the skeleton is actually shielded from thyroid hormone influence. Enzymes in developing bone tissue are set up to inactivate thyroid hormone rather than activate it, keeping thyroid signaling very low until later in pregnancy when it becomes needed for proper bone maturation.22Bone. Deiodinase-mediated thyroid hormone inactivation minimizes thyroid hormone signaling in the early development of fetal skeleton This enzymatic safeguard flips around the time of birth, after which thyroid hormone becomes a central driver of skeletal growth.
Can Bone Loss From Thyroid Disease Be Reversed?
The good news is that in many cases, yes. Treating hyperthyroidism allows bone to recover. A study of premenopausal women with Graves’ disease found that bone mineral density improved significantly after about 18 months of antithyroid drug therapy.23PubMed Central. Can bone loss be reversed by antithyroid drug therapy in premenopausal women with Graves’ disease? Surgical management tells a similar story: total thyroidectomy for hyperthyroidism improved bone density at the hip and spine as early as six months after surgery, even in patients who were also vitamin D deficient.24PubMed. Rapid restoration of bone mass after surgical management of hyperthyroidism: A prospective case control study in Southern India
For people who have already developed osteoporosis from thyroid disease, the first step is bringing thyroid levels under control. Once that is done, standard osteoporosis treatments such as bisphosphonates, calcitonin, or selective estrogen receptor modulators can be considered.25PubMed Central. Mechanisms and Treatment Options for Hyperthyroid-Induced Osteoporosis: A Narrative Review But as mentioned earlier, ongoing TSH suppression can reduce how well these medications work, so doctors need to weigh the cancer recurrence risk against bone health when setting the target TSH level.
Tracking Bone Health During Thyroid Treatment
Standard bone density scans (DEXA scans) remain the primary tool for monitoring, but blood markers of bone turnover are increasingly useful. In patients with Graves’ disease, markers of both bone formation and bone breakdown are elevated compared to people with normal thyroid function and decrease after treatment.26PubMed Central. Predictive value of bone turnover markers and thyroid indicators for bone metabolism in GD patients after treatment
Research using high-resolution imaging found that changes in specific bone turnover markers correlated with actual changes in bone microarchitecture during thyroid treatment, particularly in cortical bone at the shin. One marker of bone breakdown (CTX-I) appeared most useful for identifying bone damage in untreated thyroid disease, while a marker of bone formation (PINP) was better for tracking improvement during treatment.27PubMed. Do bone turnover markers reflect changes in bone microarchitecture during treatment of patients with thyroid dysfunction? These markers are not routinely ordered for everyone with a thyroid condition, but they can be helpful for clinicians managing patients at higher risk of bone complications, particularly those on long-term TSH suppression or postmenopausal women with a history of hyperthyroidism.
Why Postmenopausal Women Bear the Greatest Burden
Estrogen loss after menopause already accelerates bone breakdown. When hyperthyroidism is layered on top of that, the two processes compound each other. Menopausal estrogen depletion accelerates bone density loss, and hyperthyroidism adds further resorptive drive.28PubMed Central. Thyroid Dysfunction in Peri- and Postmenopausal Women-Cumulative Risks This is why most clinical guidelines emphasize bone density monitoring in postmenopausal women with any form of thyroid dysfunction, including subclinical hyperthyroidism and medically induced TSH suppression.
Premenopausal women appear to be substantially more protected. As discussed earlier, long-term TSH suppression therapy did not significantly lower bone density in premenopausal women, and antithyroid drug treatment restored bone density relatively quickly in younger women with Graves’ disease. Estrogen seems to provide a buffer that limits how much damage excess thyroid hormone can do to the skeleton. Once that buffer is gone, the bone effects of even mild thyroid overactivity become much more clinically relevant.
Thyroid-Related Osteoarthritis
Most of the conversation around thyroid disease and bone focuses on osteoporosis, but there is growing recognition that abnormal thyroid signaling may also contribute to osteoarthritis. Abnormal thyroid hormone signaling has been identified as a novel risk factor for osteoarthritis, a connection that has emerged from studies in animals with altered thyroid hormone pathways.29PubMed Central. Role of Thyroid Hormones in Skeletal Development and Bone Maintenance The research on this link is still in earlier stages compared to the osteoporosis evidence, but it suggests that thyroid hormones affect not just bone density but also the cartilage and joint structures that deteriorate in osteoarthritis. For people with longstanding thyroid disease who develop joint pain, this connection may be worth discussing with a doctor, even though thyroid-related osteoarthritis is not yet part of standard screening guidelines.